AlloCSC 02

Drug Profile

AlloCSC 02

Alternative Names: AlloCSC-02; Allogenic Cardiac Stem Cells - TiGenix

Latest Information Update: 21 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coretherapix
  • Developer TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiomyopathies

Most Recent Events

  • 31 Jul 2015 Coretherapix has been acquired by TiGenix
  • 31 Jul 2015 Preclinical trials in Cardiomyopathy in Belgium (Intracardiac)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top